- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Beta sheets.
Displaying page 1 of 1.
EudraCT Number: 2017-002126-20 | Sponsor Protocol Number: PID13341 | Start Date*: 2018-08-13 | ||||||||||||||||
Sponsor Name:University of Oxford | ||||||||||||||||||
Full Title: Interleukin-2 therapy of Autoimmunity in Diabetes: ITAD | ||||||||||||||||||
Medical condition: Type 1 Diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005668-28 | Sponsor Protocol Number: AGAL06207 | Start Date*: 2008-07-29 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (agalsidase beta) in Treatment-Naive Male Pediatric Patients with Fabry Disease Without Severe Symp... | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) PT (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003656-35 | Sponsor Protocol Number: E7389-G000-211 | Start Date*: 2006-03-14 |
Sponsor Name:Eisai Limited | ||
Full Title: A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to... | ||
Medical condition: Locally advanced or metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Completed) ES (Completed) GB (Completed) AT (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000679-90 | Sponsor Protocol Number: SPD489-325 | Start Date*: 2009-04-08 | |||||||||||
Sponsor Name:Shire Pharmaceutical Development Limited | |||||||||||||
Full Title: A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and ... | |||||||||||||
Medical condition: Attention Deficit / Hyperactivity Disorder (ADHD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) FR (Completed) ES (Completed) NL (Completed) SE (Completed) BE (Completed) IT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
